Novo Nordisk’s Ozempic (semaglutide) drug is now available to be prescribed in the UK, it has been confirmed.

Ozempic, developed by Danish pharmaceutical company Novo Nordisk, is a once-weekly GLP-1 analogue injection that works by mimicking a hormone that lowers post-meal blood glucose levels. It reduces blood glucose by stimulating insulin, inhibiting glucagon and slowing down digestion.

The drug previously received European approval in February 2018 and was approved in the US back in 2017.

The EU licensing was based on findings from the SUSTAIN trial which demonstrated Ozempic had positive impacts on blood glucose and weight loss, and also led to people experiencing cardiovascular benefits.

Ozempic is recommended for use alongside diet and exercise as primary therapy when metformin is considered inappropriate for a person’s treatment.

Some of the possible side effects of Ozempic include pancreas inflammation, changes in vision, kidney problems and allergic reactions. Anyone who experiences any related issues must speak to their healthcare provider immediately.

Research is also progressing into oral semaglutide, which was assessed for cardiac safety in a recent trial and found to reduce the risk of adverse cardiovascular events.

Editor’s note: It is possible for people with type 2 diabetes to be medication-free through eating a healthy real-food diet and getting regular exercise. Visit our award-winning Low Carb Program to find out how going low carb can also help weight loss and improving overall health.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…